2,3-二氯-4-羟基吡啶 | 1174047-06-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,3-二氯-4-羟基吡啶
• 英文名称: 2,3-dichloropyridin-4-ol
• 英文别名: 2,3-dichloro-1H-pyridin-4-one
• CAS: 1174047-06-3
• 化学式: C₅H₃Cl₂NO
• 分子量: 163.991
• InChiKey: OIIQOSKJOINELL-UHFFFAOYSA-N

物化性质

• 沸点：
  372.3±37.0 °C(Predicted)
• 密度：
  1.561±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319

反应信息

• 作为反应物：
  描述：

  2,3-二氯-4-羟基吡啶 在 (2-dicyclohexylphosphino-2’,6’-diisopropoxy-1,1‘-biphenyl)[2-(2’-methylamino-1,1’-biphenyl)]palladium(II) methanesulfonate 、 caesium carbonate 、 2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 36.0h， 生成 (R)-N-[(3S)-1'-{5-[(2,3-dichloropyridin-4-yl)oxy]pyrazin-2-yl}-1,3-dihydrospiro[indene-2,4'-piperidin]-3-yl]-2-methylpropane-2-sulfinamide
  参考文献：
  名称：

  WO2019183367A5

  摘要：

  公开号：

  WO2019183367A5
• 作为产物：
  描述：

  2,3-二氯吡啶 在 正丁基锂 、 硼酸三异丙酯 、 二异丙胺 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 以60.5%的产率得到2,3-二氯-4-羟基吡啶
  参考文献：
  名称：

  HETEROCYCLIC DERIVATIVE AND USE THEREOF

  摘要：

  本发明公开了一种如通式(I)所示的TAM家族激酶和/或Ron激酶抑制剂化合物，及其药学上可接受的盐、酯、立体异构体和异构体，含有该化合物的药剂组合物和药剂制备，以及该化合物的用途。该化合物可以抑制异常表达的TAM家族激酶/Ron激酶受体及其配体介导的疾病。该化合物可以通过抑制TAM家族激酶/Ron激酶，从而逆转肿瘤微环境中的免疫抑制环境，抑制肿瘤的生长、迁移和/或抗药性表现，发挥抗肿瘤免疫作用和抗肿瘤效果。每个基团的定义在说明书中进行了详细描述。

  公开号：

  EP4036086A1

文献信息

• [EN] 1,2,4-TRIAZINE-4-AMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZINE-4-AMINE
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2011095625A1

  公开（公告）日：2011-08-11

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.

  根据该发明提供了一种A1式化合物，可能对通过抑制A1-A2b或特别是A2a受体而得到改善的疾病或紊乱治疗有用，其中A1式化合物具有以下结构，其中，A代表Cy1或HetA；Cy1代表一个由一个、两个或三个环组成的5-至14-成员芳香、完全饱和或部分不饱和的碳环系统，该Cy1基团可选择地被一个或多个R4a取代基所取代；HetA代表一个由一个、两个或三个环组成的5-至14-成员杂环基团，可能是芳香、完全饱和或部分不饱和的，并且含有从O、S和N中选择的一个或多个杂原子，该杂环基团可能包括一个、两个或三个环，且该HetA基团可选择地被一个或多个R4b取代基所取代；B代表Cy2或HetB；Cy2代表一个由一个或两个环组成的3-至10-成员芳香、完全饱和或部分不饱和的碳环系统，该Cy2基团可选择地被一个或多个R4c取代基所取代；HetB代表一个由一个或两个环组成的3-至10-成员杂环基团，可能是芳香、完全饱和或部分不饱和的，并且含有从O、S和N中选择的一个或多个杂原子，该杂环基团可能包括一个或两个环，且该HetB基团可选择地被一个或多个R4d取代基所取代。
• [EN] 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER<br/>[FR] PROCÉDÉ DE PRÉPARATION DE COMPOSÉS DE PYRIDINONE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009094427A1

  公开（公告）日：2009-07-30

  Disclosed herein is a process for preparing a compound of Formula (I), comprising the steps of: (a) reacting an aniline compound of Formula (II) and an carboxylic acid compound of Formula (III) or an activated carboxylic acid compound thereof, to provide a compound of Formula (IV); and (b) converting said protected amine group attached to said compound of Formula (IV) to an amine group to provide said compound of Formula (I); wherein PAm is a protected amine group. Processes to prepare the compounds of Formulae (II), (III), and (IV) are also disclosed.

  本文揭示了一种制备式（I）化合物的方法，包括以下步骤：（a）反应式（II）的苯胺化合物和式（III）的羧酸化合物或其活化的羧酸化合物，以提供式（IV）的化合物; （b）将附加在式（IV）的保护胺基转化为胺基，以提供式（I）的化合物；其中PAm是保护胺基。本文还揭示了制备式（II）、（III）和（IV）化合物的方法。
• 1,2,4-TRIAZINE-4-AMINE DERIVATIVES
  申请人：Congreve Miles Stuart

  公开号：US20130029963A1

  公开（公告）日：2013-01-31

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.

  根据本发明提供了一种A1式化合物，该化合物可能有用于治疗通过抑制A1-A2bor，特别是A2a受体而改善的疾病或疾病状态，其中A1式化合物具有以下结构，其中A代表Cy1或HetA；Cy1代表一个5到14个成员的芳香族、完全饱和或部分不饱和的碳环状环系，包括一个、两个或三个环，该Cy1基团可以被一个或多个R4a取代；HetA代表一个5到14个成员的杂环基团，可能是芳香族、完全饱和或部分不饱和的，并且其中包含一个或多个从O、S和N中选择的杂原子，该杂环基团可以包括一个、两个或三个环，该HetA基团可以被一个或多个R4b取代；B代表Cy2或HetB；Cy2代表一个3到10个成员的芳香族、完全饱和或部分不饱和的碳环状环系，包括一个或两个环，该Cy2基团可以被一个或多个R4c取代；HetB代表一个3到10个成员的杂环基团，可能是芳香族、完全饱和或部分不饱和的，并且其中包含一个或多个从O、S和N中选择的杂原子，该杂环基团可以包括一个或两个环，该HetB基团可以被一个或多个R4d取代。
• 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20140012007A1

  公开（公告）日：2014-01-09

  Disclosed herein is a process for preparing a compound of Formula (I), comprising the steps of: (a) reacting an aniline compound of Formula (II) and an carboxylic acid compound of Formula (III) or an activated carboxylic acid compound thereof, to provide a compound of Formula (IV); and (b) converting said protected amine group attached to said compound of Formula (IV) to an amine group to provide said compound of Formula (I); wherein PAm is a protected amine group. Processes to prepare the compounds of Formulae (II), (III), and (IV) are also disclosed.

  本文公开了一种制备式（I）化合物的方法，包括以下步骤：(a)反应式（II）的苯胺化合物和式（III）的羧酸化合物或其活化羧酸化合物，得到式（IV）的化合物；(b)将附加在式（IV）化合物上的受保护胺基转化为胺基，以提供式（I）的化合物；其中PAm是受保护的胺基团。还公开了制备式（II）、（III）和（IV）化合物的方法。
• 1,2,4-triazine-4-amine derivatives
  申请人：Heptares Therapeutics Limited

  公开号：US10112923B2

  公开（公告）日：2018-10-30

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocylic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.

  根据本发明，提供了一种式 A1 的化合物，该化合物可用于治疗通过抑制 A1-A2b 或特别是 A2a 受体而改善的病症或紊乱，其中式 A1 的化合物具有如下结构，其中，A 代表 Cy1 或 HetA；Cy1 代表由一个、两个或三个环组成的 5 至 14 元芳香族、完全饱和或部分不饱和碳环系统，该 Cy1 基团任选被一个或多个 R4a 取代基取代；HetA 代表 5 至 14 元杂环基团，可以是芳香族、完全饱和或部分不饱和的杂环基团，含有一个或多个选自 O、S 和 N 的杂原子，该杂环基团可以包括一个、两个或三个环，该 HetA 基团任选被一个或多个 R4b 取代基取代；B 代表 Cy2 或 HetB；Cy2 代表由一个或两个环组成的 3 至 10 元芳香族、完全饱和或 部分不饱和碳环系统，其 Cy2 基团可任选被一个或多个 R4c 取代基取代；HetB 代表 3 至 10 元杂环基团，可以是芳香族、完全饱和或部分不饱和的杂环基团，其中含有一个或多个选自 O、S 和 N 的杂原子，该杂环基团可包括一个或两个环，该 HetB 基团可任选被一个或多个 R4d 取代基取代。